A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

NCT07705334 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors
Triple Negative Breast Cancer (TNBC)
HR+ Breast Cancer
Colon Cancer
Gastric Cancer
Hepatecellular Carcinoma
NSCLC (Advanced Non-small Cell Lung Cancer)
Mesothelioma
Pancreatic Carcinoma Metastatic
Hormone Refractory Prostate Cancer
Soft Tissue Sarcomas

Interventions

DRUG: SHY-ONC6

Sponsor

SHY Therapeutics